Skip to content

Insulin Pump-RT Advisor (IPRA©): a Decision Support Software for Diabetic Patients Treated by Insulin Pump and Using Continuous Glucose Monitoring. Experimental Study. Evaluation by an Expert Patient Panel.

Prospective Study, Insulin Pump-RT Advisor (IPRA©): a Decision Support Software for Diabetic Patients Treated by Insulin Pump and Using Continuous Glucose Monitoring. Experimental Study. Evaluation by an Expert Patient Panel.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01883024
Acronym
IPRA
Enrollment
6
Registered
2013-06-21
Start date
2013-06-30
Completion date
2013-09-30
Last updated
2023-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes

Keywords

Real time continuous glucose monitoring, decision support software, smartphone application.

Brief summary

The purpose of the study is to assess the relevance of the advices provided by the IPRA© smartphone application for guiding the responses of insulin pump treated type 1 diabetes patients using real-time continuous glucose monitoring.

Detailed description

Patients will be asked to evaluate the IPRA advices by connecting to IPRA© application by using their smartphone, 30 times a week for two weeks. At the end of this two week period, a satisfaction questionnaire will be completed.

Interventions

OTHERInsulin Pump
OTHERContinuous glucose monitoring

Sponsors

Rennes University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* men and women ≥ 18 years of age, * patients with type 1 diabetes for more than 2 years, * patients treated by insulin pump for more than 6 months, * patients using of real-time continuous glucose monitoring for more than 3 months, * patients able to evaluate the IPRA advices by connecting to IPRA© application 30 times a week, * patient able to provide written informed consent, * patient able to provide written non-disclosure agreement

Exclusion criteria

* pregnancy or breastfeeding, * current infectious disease, * patients with no smartphone® or Internet access, * adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty

Design outcomes

Primary

MeasureTime frameDescription
Patient agreement with the IPRA© advices: global rate of agreement, according to advice subtypes, according to blood glucose levels, according to the situations (pre or post-meal, bedtime)3 monthsAssessment of the relevance of the advices provided by the IPRA© smartphone application for guiding the responses of insulin pump treated type 1 diabetes patients using real-time continuous glucose monitoring.

Secondary

MeasureTime frameDescription
Assessment of similarity between patient decisions and IPRA© advices3 monthsAssessment of patient satisfaction about using IPRA© and their frequency of use. Recording of the changes proposed by the expert patients.
Assessment of changes proposed by the experts3 months
Assessment of frequency of software use3 months
Assessment of patient satisfaction3 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026